Literature DB >> 7638175

Herpes simplex virus vectors overexpressing the glucose transporter gene protect against seizure-induced neuron loss.

M S Lawrence1, D Y Ho, R Dash, R M Sapolsky.   

Abstract

We have generated herpes simplex virus (HSV) vectors vIE1GT and v alpha 4GT bearing the GLUT-1 isoform of the rat brain glucose transporter (GT) under the control of the human cytomegalovirus ie1 and HSV alpha 4 promoters, respectively. We previously reported that such vectors enhance glucose uptake in hippocampal cultures and the hippocampus. In this study we demonstrate that such vectors can maintain neuronal metabolism and reduce the extent of neuron loss in cultures after a period of hypoglycemia. Microinfusion of GT vectors into the rat hippocampus also reduces kainic acid-induced seizure damage in the CA3 cell field. Furthermore, delivery of the vector even after onset of the seizure is protective, suggesting that HSV-mediated gene transfer for neuroprotection need not be carried out in anticipation of neurologic crises. Using the bicistronic vector v alpha 22 beta gal alpha 4GT, which coexpresses both GT and the Escherichia coli lacZ marker gene, we further demonstrate an inverse correlation between the extent of vector expression in the dentate and the amount of CA3 damage resulting from the simultaneous delivery of kainic acid.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7638175      PMCID: PMC41316          DOI: 10.1073/pnas.92.16.7247

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy.

Authors:  Y Ben-Ari
Journal:  Neuroscience       Date:  1985-02       Impact factor: 3.590

Review 2.  Neurotoxic action of kainic acid.

Authors:  J T Coyle
Journal:  J Neurochem       Date:  1983-07       Impact factor: 5.372

3.  Metabolic factors during prolonged seizures and their relation to nerve cell death.

Authors:  B S Meldrum
Journal:  Adv Neurol       Date:  1983

4.  Kainic acid selectively stimulates the release of endogenous excitatory acidic amino acids.

Authors:  J W Ferkany; J T Coyle
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

5.  Kainic acid neurotoxicity toward hippocampal formation: dependence on specific excitatory pathways.

Authors:  J V Nadler; G J Cuthbertson
Journal:  Brain Res       Date:  1980-08-11       Impact factor: 3.252

6.  Expression of hepatitis B virus S gene by herpes simplex virus type 1 vectors carrying alpha- and beta-regulated gene chimeras.

Authors:  M F Shih; M Arsenakis; P Tiollais; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  Effects of kainic acid in rat brain synaptosomes: the involvement of calcium.

Authors:  A Pastuszko; D F Wilson; M Erecińska
Journal:  J Neurochem       Date:  1984-09       Impact factor: 5.372

8.  Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects.

Authors:  D Y Ho; S L Fink; M S Lawrence; T J Meier; T C Saydam; R Dash; R M Sapolsky
Journal:  J Neurosci Methods       Date:  1995-04       Impact factor: 2.390

9.  Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4.

Authors:  N A DeLuca; A M McCarthy; P A Schaffer
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

10.  Influence of reduced oxygen availability on cerebral metabolic changes during bicuculline-induced seizures in rats.

Authors:  G Blennow; B Nilsson; B K Siesjö
Journal:  J Cereb Blood Flow Metab       Date:  1985-09       Impact factor: 6.200

View more
  13 in total

1.  Sparing of neuronal function postseizure with gene therapy.

Authors:  J McLaughlin; B Roozendaal; T Dumas; A Gupta; O Ajilore; J Hsieh; D Ho; M Lawrence; J L McGaugh; R Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  Adenovirus vector-directed expression of the neurotrophin-3 receptor (TrkC) in mouse astrocytes.

Authors:  N Rubio; J Abad-Rodriguez
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

Review 3.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

4.  Dual-gene, dual-cell type therapy against an excitotoxic insult by bolstering neuroenergetics.

Authors:  Tonya M Bliss; Miranda Ip; Elise Cheng; Masabumi Minami; Luc Pellerin; Pierre Magistretti; Robert M Sapolsky
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

5.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

Review 6.  Hypoxic preconditioning protects against ischemic brain injury.

Authors:  Frank R Sharp; Ruiqiong Ran; Aigang Lu; Yang Tang; Kenneth I Strauss; Todd Glass; Tim Ardizzone; Myriam Bernaudin
Journal:  NeuroRx       Date:  2004-01

7.  Neuroprotective potential of a viral vector system induced by a neurological insult.

Authors:  C R Ozawa; J J Ho; D J Tsai; D Y Ho; R M Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

8.  Mapping quantitative trait loci for seizure response to a GABAA receptor inverse agonist in mice.

Authors:  H K Gershenfeld; P E Neumann; X Li; P L St Jean; S M Paul
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

9.  Viral caspase inhibitor p35, but not crmA, is neuroprotective in the ischemic penumbra following experimental stroke.

Authors:  J H Sung; H Zhao; M Roy; R M Sapolsky; G K Steinberg
Journal:  Neuroscience       Date:  2007-07-26       Impact factor: 3.590

10.  Herpes Virus Amplicon Vectors.

Authors:  Suresh de Silva; William J Bowers
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.